Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PI3Kδ Inhibitor Linperlisib Combined With HDAC Inhibitor Chidamide Versus CHOP in Patients With Peripheral T-cell Lymphoma: a Multicenter, Open Label, Phase Ib/II Study

NCT06421948 is registered in ClinicalTrials.gov with Yanyan Liu as lead sponsor.

NCT NCT06421948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06421948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PI3Kδ Inhibitor Linperlisib Combined With HDAC Inhibitor Chidamide Versus CHOP in Patients With Peripheral T-cell Lymphoma: a Multicenter, Open Label, Phase Ib/II Study
Lead sponsor
Yanyan Liu
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 25, 2024
Completion date
December 31, 2027
Enrollment
134 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma